Engineering therapeutic antibodies to combat infectious diseases

Current Opinion in Chemical Engineering

Volumn 19, Issue , 2018, Pages 131-141

  Wagner, Ellen K ^a   Maynard, Jennifer A ^a  

^a The University of Texas at Austin   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTICS; BACTERIA; BIOLOGY; BODY FLUIDS; DISEASE CONTROL; DISEASES; ENZYME INHIBITION;

ANTIBIOTIC-RESISTANT BACTERIA; ANTIBODY ENGINEERING; ANTIBODY MANUFACTURING; INFECTIOUS DISEASE; PSEUDOMONAS AERUGINOSA; SERUM THERAPY; STAPHYLOCOCCUS AUREUS; THERAPEUTIC ANTIBODIES;

ANTIBODIES;

EID: 85042844270     PISSN: None     EISSN: 22113398     Source Type: Journal    
DOI: 10.1016/j.coche.2018.01.007     Document Type: Review

References (64)

1. Ecker, D.M., Jones, S.D., Levine, H.L., The therapeutic monoclonal antibody market. MAbs 7 (2015), 9–14.
2. Hay, M., Thomas, D.W., Craighead, J.L., Economides, C., Rosenthal, J., Clinical development success rates for investigational drugs. Nat Biotechnol 32 (2014), 40–51.
3. Hey, A., History and practice: antibodies in infectious diseases. Microbiol Spectr, 3, 2015 AID-0026-2014.
4. McLellan, J.S., Chen, M., Kim, A., Yang, Y., Graham, B.S., Kwong, P.D., Structural basis of respiratory syncytial virus neutralization by motavizumab. Nat Struct Mol Biol 17 (2010), 248–250.
5. Meissner, H.C., Long, S.S., American Academy of Pediatrics Committee on Infectious D, Committee on F, Newborn, Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 112 (2003), 1447–1452.
6. Orth, P., Xiao, L., Hernandez, L.D., Reichert, P., Sheth, P.R., Beaumont, M., Yang, X., Murgolo, N., Ermakov, G., DiNunzio, E., et al. Mechanism of action and epitopes of Clostridium difficile toxin B-neutralizing antibody bezlotoxumab revealed by X-ray crystallography. J Biol Chem 289 (2014), 18008–18021.
7. Oganesyan, V., Peng, L., Damschroder, M.M., Cheng, L., Sadowska, A., Tkaczyk, C., Sellman, B.R., Wu, H., Dall'Acqua, W.F., Mechanisms of neutralization of a human anti-alpha-toxin antibody. J Biol Chem 289 (2014), 29874–29880.
8. Yermakova, A., Klokk, T.I., Cole, R., Sandvig, K., Mantis, N.J., Antibody-mediated inhibition of ricin toxin retrograde transport. MBio, 5, 2014, e00995.
9. Takahashi, T., Joshi, S.G., Al-Saleem, F., Ancharski, D., Singh, A., Nasser, Z., Simpson, L.L., Localization of the sites and characterization of the mechanisms by which anti-light chain antibodies neutralize the actions of the botulinum holotoxin. Vaccine 27 (2009), 2616–2624.
10. Cohen, T.S., Hilliard, J.J., Jones-Nelson, O., Keller, A.E., O'Day, T., Tkaczyk, C., DiGiandomenico, A., Hamilton, M., Pelletier, M., Wang, Q., et al. Staphylococcus aureus alpha toxin potentiates opportunistic bacterial lung infections. Sci Transl Med, 8, 2016 329ra331 The authors report that antibody-mediated neutralization of the S. aureus alpha toxin can indirectly provide protection against other gram negative pathogens by protecting immune functions such as acidification of the macrophage lysosome.
11. Migone, T.S., Subramanian, G.M., Zhong, J., Healey, L.M., Corey, A., Devalaraja, M., Lo, L., Ullrich, S., Zimmerman, J., Chen, A., et al. Raxibacumab for the treatment of inhalational anthrax. N Engl J Med 361 (2009), 135–144.
12. Yamamoto, B.J., Shadiack, A.M., Carpenter, S., Sanford, D., Henning, L.N., Gonzales, N., O'Connor, E., Casey, L.S., Serbina, N.V., Obiltoxaximab prevents disseminated Bacillus anthracis infection and improves survival during pre- and postexposure prophylaxis in animal models of inhalational anthrax. Antimicrob Agents Chemother 60 (2016), 5796–5805.
13. Liu, S., Crown, D., Miller-Randolph, S., Moayeri, M., Wang, H., Hu, H., Morley, T., Leppla, S.H., Capillary morphogenesis protein-2 is the major receptor mediating lethality of anthrax toxin in vivo. Proc Natl Acad Sci U S A 106 (2009), 12424–12429.
14. Liu, S., Zhang, Y., Moayeri, M., Liu, J., Crown, D., Fattah, R.J., Wein, A.N., Yu, Z.X., Finkel, T., Leppla, S.H., Key tissue targets responsible for anthrax-toxin-induced lethality. Nature 501 (2013), 63–68.
15. Chen, Z., Moayeri, M., Purcell, R., Monoclonal antibody therapies against anthrax. Toxins (Basel) 3 (2011), 1004–1019.
16. Lowy, I., Molrine, D.C., Leav, B.A., Blair, B.M., Baxter, R., Gerding, D.N., Nichol, G., Thomas, W.D. Jr., Leney, M., Sloan, S., et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 362 (2010), 197–205.
17. Wilcox, M.H., Gerding, D.N., Poxton, I.R., Kelly, C., Nathan, R., Birch, T., Cornely, O.A., Rahav, G., Bouza, E., Lee, C., et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med 376 (2017), 305–317.
18. Sause, W.E., Buckley, P.T., Strohl, W.R., Lynch, A.S., Torres, V.J., Antibody-based biologics and their promise to combat Staphylococcus aureus infections. Trends Pharmacol Sci 37 (2016), 231–241.
19. Wang, X.Z., Coljee, V.W., Maynard, J.A., Back to the future: recombinant polyclonal antibody therapeutics. Curr Opin Chem Eng 2 (2013), 405–415.
20. Proposed rules for fixed-combination and co-packaged drugs: applications for approval and combinations of active ingredients under consideration for inclusion in an over-the-counter monograph. Fed Reg 80 (2015), 79776–79795.
21. Bouvin-Pley, M., Morgand, M., Meyer, L., Goujard, C., Moreau, A., Mouquet, H., Nussenzweig, M., Pace, C., Ho, D., Bjorkman, P.J., et al. Drift of the HIV-1 envelope glycoprotein gp120 toward increased neutralization resistance over the course of the epidemic: a comprehensive study using the most potent and broadly neutralizing monoclonal antibodies. J Virol 88 (2014), 13910–13917.
22. Kong, R., Louder, M.K., Wagh, K., Bailer, R.T., deCamp, A., Greene, K., Gao, H., Taft, J.D., Gazumyan, A., Liu, C., et al. Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes. J Virol 89 (2015), 2659–2671.
23. Qiu, X., Audet, J., Lv, M., He, S., Wong, G., Wei, H., Luo, L., Fernando, L., Kroeker, A., Fausther Bovendo, H., et al. Two-mAb cocktail protects macaques against the Makona variant of Ebola virus. Sci Transl Med, 8, 2016 329ra333.
24. Kugelman, J.R., Kugelman-Tonos, J., Ladner, J.T., Pettit, J., Keeton, C.M., Nagle, E.R., Garcia, K.Y., Froude, J.W., Kuehne, A.I., Kuhn, J.H., et al. Emergence of Ebola virus escape variants in infected nonhuman primates treated with the MB-003 antibody cocktail. Cell Rep 12 (2015), 2111–2120.
25. Nowakowski, A., Wang, C., Powers, D.B., Amersdorfer, P., Smith, T.J., Montgomery, V.A., Sheridan, R., Blake, R., Smith, L.A., Marks, J.D., Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A 99 (2002), 11346–11350.
26. Nguyen, A.W., Wagner, E.K., Laber, J.R., Goodfield, L.L., Smallridge, W.E., Harvill, E.T., Papin, J.F., Wolf, R.F., Padlan, E.A., Bristol, A., et al. A cocktail of humanized anti-pertussis toxin antibodies limits disease in murine and baboon models of whooping cough. Sci Transl Med, 7, 2015 316ra195 This work shows that two antibodies targeting just the pertussis toxin can mitigate the symptoms of whooping cough when administered to non-human primates three days after infection, a disease with >20 virulence factors and no serological correlate of protection.
27. Dutta, K., Varshney, A.K., Franklin, M.C., Goger, M., Wang, X., Fries, B.C., Mechanisms mediating enhanced neutralization efficacy of staphylococcal enterotoxin B by combinations of monoclonal antibodies. J Biol Chem 290 (2015), 6715–6730.
28. Brinkmann, U., Kontermann, R.E., The making of bispecific antibodies. MAbs 9 (2017), 182–212.
29. Wagner, E.K., Wang, X., Bui, A., Maynard, J.A., Synergistic neutralization of pertussis toxin by a bispecific antibody in vitro and in vivo. Clin Vaccine Immunol 23 (2016), 851–862.
30. DiGiandomenico, A., Keller, A.E., Gao, C., Rainey, G.J., Warrener, P., Camara, M.M., Bonnell, J., Fleming, R., Bezabeh, B., Dimasi, N., et al. A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci Transl Med, 6, 2014 262ra155 The bispecific antibody reported here targets the common exopolysaccharide Psl, which localizes the antibody to the bacteria and mediates phagocytosis, as well as the less common PcrV protein. This supports empirical analysis of multiple bispecific antibody architectures in order to find a format that is most compatible with ligand binding and thus most protective.
31. Thanabalasuriar, A., Surewaard, B.G., Willson, M.E., Neupane, A.S., Stover, C.K., Warrener, P., Wilson, G., Keller, A.E., Sellman, B.R., DiGiandomenico, A., et al. Bispecific antibody targets multiple Pseudomonas aeruginosa evasion mechanisms in the lung vasculature. J Clin Invest 127 (2017), 2249–2261 This works demonstrates the mechanism of action for a bispecific antibody targeting the Psl and PcrV antigens of P. aeruginosa which was not observed for the antibody mixture. This suggests that the binding sites work together to target the bacteria to neutrophil phagosomes and support enhanced killing.
32. Bezabeh, B., Fleming, R., Fazenbaker, C., Zhong, H., Coffman, K., Yu, X.Q., Leow, C.C., Gibson, N., Wilson, S., Stover, C.K., et al. Insertion of scFv into the hinge domain of full-length IgG1 monoclonal antibody results in tetravalent bispecific molecule with robust properties. MAbs 9 (2017), 240–256.
33. Wec, A.Z., Nyakatura, E.K., Herbert, A.S., Howell, K.A., Holtsberg, F.W., Bakken, R.R., Mittler, E., Christin, J.R., Shulenin, S., Jangra, R.K., et al. A “Trojan horse” bispecific-antibody strategy for broad protection against ebolaviruses. Science 354 (2016), 350–354 The authors report a bispecific antibody able to co-localize with intracellular ebola viruses and block viral-eukaryotic membrane fusion in the endosome.
34. Bargou, R., Leo, E., Zugmaier, G., Klinger, M., Goebeler, M., Knop, S., Noppeney, R., Viardot, A., Hess, G., Schuler, M., et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321 (2008), 974–977.
35. Sloan, D.D., Lam, C.Y., Irrinki, A., Liu, L., Tsai, A., Pace, C.S., Kaur, J., Murry, J.P., Balakrishnan, M., Moore, P.A., et al. Targeting HIV reservoir in infected CD4 T cells by dual-affinity re-targeting molecules (DARTs) that bind HIV envelope and recruit cytotoxic T cells. PLoS Pathog, 11, 2015, e1005233.
36. Yang, H., Buisson, S., Bossi, G., Wallace, Z., Hancock, G., So, C., Ashfield, R., Vuidepot, A., Mahon, T., Molloy, P., et al. Elimination of latently HIV-infected cells from antiretroviral therapy-suppressed subjects by engineered immune-mobilizing T-cell receptors. Mol Ther 24 (2016), 1913–1925.
37. Tkaczyk, C., Hamilton, M.M., Sadowska, A., Shi, Y., Chang, C.S., Chowdhury, P., Buonapane, R., Xiao, X., Warrener, P., Mediavilla, J., et al. Targeting alpha toxin and ClfA with a multimechanistic monoclonal-antibody-based approach for prophylaxis of serious Staphylococcus aureus disease. MBio, 2016, 7 Provides proof-of-concept for simultaneous treatment with antibodies targeting the S. aureus ClfA protein and alpha-toxin.
38. Tkaczyk, C., Kasturirangan, S., Minola, A., Jones-Nelson, O., Gunter, V., Shi, Y.Y., Rosenthal, K., Aleti, V., Semenova, E., Warrener, P., et al. Multimechanistic monoclonal antibodies (MAbs) targeting Staphylococcus aureus alpha-toxin and clumping factor a: activity and efficacy comparisons of a MAb combination and an engineered bispecific antibody approach. Antimicrob Agents Chemother, 61, 2017.
39. Ward, E.S., Devanaboyina, S.C., Ober, R.J., Targeting FcRn for the modulation of antibody dynamics. Mol Immunol 67 (2015), 131–141.
40. Griffin, M.P., Khan, A.A., Esser, M.T., Jensen, K., Takas, T., Kankam, M.K., Villafana, T., Dubovsky, F., Safety, tolerability, and pharmacokinetics of MEDI8897, the respiratory syncytial virus prefusion F-targeting monoclonal antibody with an extended half-life, in healthy adults. Antimicrob Agents Chemother, 61, 2017.
41. Zhu, Q., McLellan, J.S., Kallewaard, N.L., Ulbrandt, N.D., Palaszynski, S., Zhang, J., Moldt, B., Khan, A., Svabek, C., McAuliffe, J.M., et al. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Sci Transl Med, 2017, 9 The authors describe a new antibody binding a neutralizing epitope on the RSV F protein which is only present on the prefusion conformation. When formatted as a human IgG1 with the half-life extending YTE changes in the Fc region, it is nine-fold more effective than Palivizumab in rats and has a three-fold extended half-life in cynomolgous monkeys.
42. Ko, S.Y., Pegu, A., Rudicell, R.S., Yang, Z.Y., Joyce, M.G., Chen, X., Wang, K., Bao, S., Kraemer, T.D., Rath, T., et al. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature 514 (2014), 642–645.
43. Grevys, A., Bern, M., Foss, S., Bratlie, D.B., Moen, A., Gunnarsen, K.S., Aase, A., Michaelsen, T.E., Sandlie, I., Andersen, J.T., Fc engineering of human IgG1 for altered binding to the neonatal Fc receptor affects Fc effector functions. J Immunol 194 (2015), 5497–5508.
44. Dall'Acqua, W.F., Kiener, P.A., Wu, H., Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 281 (2006), 23514–23524.
45. Wang, T.T., Sewatanon, J., Memoli, M.J., Wrammert, J., Bournazos, S., Bhaumik, S.K., Pinsky, B.A., Chokephaibulkit, K., Onlamoon, N., Pattanapanyasat, K., et al. IgG antibodies to dengue enhanced for FcgammaRIIIA binding determine disease severity. Science 355 (2017), 395–398.
46. Lo, M., Kim, H.S., Tong, R.K., Bainbridge, T.W., Vernes, J.M., Zhang, Y., Lin, Y.L., Chung, S., Dennis, M.S., Zuchero, Y.J., et al. Effector-attenuating substitutions that maintain antibody stability and reduce toxicity in mice. J Biol Chem 292 (2017), 3900–3908.
47. Li, T., DiLillo, D.J., Bournazos, S., Giddens, J.P., Ravetch, J.V., Wang, L.X., Modulating IgG effector function by Fc glycan engineering. Proc Natl Acad Sci U S A 114 (2017), 3485–3490.
48. Hiatt, A., Bohorova, N., Bohorov, O., Goodman, C., Kim, D., Pauly, M.H., Velasco, J., Whaley, K.J., Piedra, P.A., Gilbert, B.E., et al. Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proc Natl Acad Sci U S A 111 (2014), 5992–5997.
49. Hua, L., Cohen, T.S., Shi, Y., Datta, V., Hilliard, J.J., Tkaczyk, C., Suzich, J., Stover, C.K., Sellman, B.R., MEDI4893* promotes survival and extends the antibiotic treatment window in a Staphylococcus aureus immunocompromised pneumonia model. Antimicrob Agents Chemother 59 (2015), 4526–4532.
50. Zhou, C., Lehar, S., Gutierrez, J., Rosenberger, C.M., Ljumanovic, N., Dinoso, J., Koppada, N., Hong, K., Baruch, A., Carrasco-Triguero, M., et al. Pharmacokinetics and pharmacodynamics of DSTA4637A: a novel THIOMAB antibody antibiotic conjugate against Staphylococcus aureus in mice. MAbs 8 (2016), 1612–1619.
51. Lehar, S.M., Pillow, T., Xu, M., Staben, L., Kajihara, K.K., Vandlen, R., DePalatis, L., Raab, H., Hazenbos, W.L., Morisaki, J.H., et al. Novel antibody-antibiotic conjugate eliminates intracellular S. aureus. Nature 527 (2015), 323–328 The authors demonstrate use of an antibody-drug conjugate to access hidden bacterial reservoirs. They identified a cell wall binding antibody to target bacteria for phagocytosis. After transport to the lysosome, endogenous proteases released a modified rifamycin antibiotic which killed bacteria.
52. McLellan, J.S., Chen, M., Leung, S., Graepel, K.W., Du, X., Yang, Y., Zhou, T., Baxa, U., Yasuda, E., Beaumont, T., et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340 (2013), 1113–1117.
53. Palomo, C., Mas, V., Detalle, L., Depla, E., Cano, O., Vazquez, M., Stortelers, C., Melero, J.A., Trivalency of a nanobody specific for the human respiratory syncytial virus fusion glycoprotein drastically enhances virus neutralization and impacts escape mutant selection. Antimicrob Agents Chemother 60 (2016), 6498–6509.
54. Sawa, T., Ito, E., Nguyen, V.H., Haight, M., Anti-PcrV antibody strategies against virulent Pseudomonas aeruginosa. Hum Vaccin Immunother 10 (2014), 2843–2852.
55. Warrener, P., Varkey, R., Bonnell, J.C., DiGiandomenico, A., Camara, M., Cook, K., Peng, L., Zha, J., Chowdury, P., Sellman, B., et al. A novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models. Antimicrob Agents Chemother 58 (2014), 4384–4391.
56. Ganesh, V.K., Liang, X., Geoghegan, J.A., Cohen, A.L.V., Venugopalan, N., Foster, T.J., Hook, M., Lessons from the crystal structure of the S. aureus surface protein clumping factor A in complex with tefibazumab, an inhibiting monoclonal antibody. EBioMedicine 13 (2016), 328–338.
57. Rouha, H., Badarau, A., Visram, Z.C., Battles, M.B., Prinz, B., Magyarics, Z., Nagy, G., Mirkina, I., Stulik, L., Zerbs, M., et al. Five birds, one stone: neutralization of alpha-hemolysin and 4 bi-component leukocidins of Staphylococcus aureus with a single human monoclonal antibody. MAbs 7 (2015), 243–254 The authors report identification of a single antibody able to bind and neutralize the S. aureus alpha toxin and four related leukocidins with picomolar affinities, despite the low level of ∼26% amino acid identity among the toxins.
58. Kallewaard, N.L., Corti, D., Collins, P.J., Neu, U., McAuliffe, J.M., Benjamin, E., Wachter-Rosati, L., Palmer-Hill, F.J., Yuan, A.Q., Walker, P.A., et al. Structure and function analysis of an antibody recognizing all influenza A subtypes. Cell 166 (2016), 596–608 An antibody binding a novel neutralizing epitope that is highly conserved across all influenza A subtypes is reported.
59. Diep, B.A., Le, V.T., Badiou, C., Le, H.N., Pinheiro, M.G., Duong, A.H., Wang, X., Dip, E.C., Aguiar-Alves, F., Basuino, L., et al. IVIG-mediated protection against necrotizing pneumonia caused by MRSA. Sci Transl Med, 8, 2016 357ra124.
60. Wang, Q., Chang, C.S., Pennini, M., Pelletier, M., Rajan, S., Zha, J., Chen, Y., Cvitkovic, R., Sadowska, A., Heidbrink Thompson, J., et al. Target-agnostic identification of functional monoclonal antibodies against Klebsiella pneumoniae multimeric MrkA fimbrial subunit. J Infect Dis 213 (2016), 1800–1808.
61. Fleishman, S.J., Whitehead, T.A., Ekiert, D.C., Dreyfus, C., Corn, J.E., Strauch, E.M., Wilson, I.A., Baker, D., Computational design of proteins targeting the conserved stem region of influenza hemagglutinin. Science 332 (2011), 816–821.
62. Entzminger, K.C., Hyun, J.M., Pantazes, R.J., Patterson-Orazem, A.C., Qerqez, A.N., Frye, Z.P., Hughes, R.A., Ellington, A.D., Lieberman, R.L., Maranas, C.D., et al. De novo design of antibody complementarity determining regions binding a FLAG tetra-peptide. Sci Rep, 7, 2017, 10295.
63. Robinson, L.N., Tharakaraman, K., Rowley, K.J., Costa, V.V., Chan, K.R., Wong, Y.H., Ong, L.C., Tan, H.C., Koch, T., Cain, D., et al. Structure-guided design of an anti-dengue antibody directed to a non-immunodominant epitope. Cell 162 (2015), 493–504.
64. Maynard, J.A., Maassen, C.B., Leppla, S.H., Brasky, K., Patterson, J.L., Iverson, B.L., Georgiou, G., Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat Biotechnol 20 (2002), 597–601.